ERBB2 and neoplasm: Predictive biomarkers for therapeutic efficacy, including hormone receptor status, HER2 protein expression levels, HER2 gene copy number, HER2 heterogeneity, histological grade, Ki-67 index, and tumor-infiltrating lymphocytes, have been explored, but no universally recognized predictive factor has been established.